Rating Action: Is STRATEC Biomedical (ETR:SBS) a Sell? DZ BANK Downgrades It

November 24, 2016 - By Peter Erickson

Rating Action: Is STRATEC Biomedical (ETR:SBS) a Sell? DZ BANK Downgrades It

STRATEC Biomedical (ETR:SBS) Downgrade

DZ BANK lowered STRATEC Biomedical (ETR:SBS)‘s stock to a “Sell” rating. The ratings change was issued to investors and clients in a a research note today.

Stratec Biomedical AG (ETR:SBS) Ratings Coverage

Out of 7 analysts covering STRATEC Biomedical (ETR:SBS), 4 rate it a “Buy”, 2 “Sell”, while 1 “Hold”. This means 57% are positive. €65 is the highest target while €47 is the lowest. The €55.40 average target is 29.44% above today’s (€42.8) stock price. STRATEC Biomedical has been the topic of 20 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was upgraded by Oddo & Cie to “Buy” on Tuesday, April 12. The stock of Stratec Biomedical AG (ETR:SBS) has “Buy” rating given on Saturday, October 1 by Oddo & Cie. Berenberg maintained it with “Hold” rating and €51 target price in Saturday, February 13 report. Berenberg maintained the shares of SBS in a report on Saturday, November 12 with “Hold” rating. Warburg Research upgraded Stratec Biomedical AG (ETR:SBS) rating on Friday, September 2. Warburg Research has “Buy” rating and €65 price target. Kepler Cheuvreux maintained the shares of SBS in a report on Thursday, March 17 with “Hold” rating. As per Friday, June 10, the company rating was upgraded by Warburg Research. The stock has “Hold” rating given by Berenberg on Tuesday, March 29. The company was upgraded on Wednesday, March 30 by HSBC. Kepler Cheuvreux maintained it with “Hold” rating and €48 target price in Thursday, July 23 report.

About 6,041 shares traded hands. Stratec Biomedical AG (ETR:SBS) has risen 23.12% since April 22, 2016 and is uptrending. It has outperformed by 17.71% the S&P500.

Analysts await Companhia de Saneamento Basico (ADR) (NYSE:SBS) to report earnings on March, 24. They expect $0.21 earnings per share, up 23.53% or $0.04 from last year’s $0.17 per share. SBS’s profit will be $146.61M for 10.33 P/E if the $0.21 EPS becomes a reality. After $0.26 actual earnings per share reported by Companhia de Saneamento Basico (ADR) for the previous quarter, Wall Street now forecasts -19.23% negative EPS growth.

STRATEC Biomedical AG is a Germany firm engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. The company has a market cap of 507.55 million EUR. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. It has a 36.39 P/E ratio. STRATEC’s partners market Company’s products to pharmaceutical laboratories, blood banks and research institutes throughout the world.

According to Zacks Investment Research, “SABESP provides public water and sewage services to residential, commercial, industrial and governmental customers in the City of Sao Paulo.”

SBS Company Profile

Companhia de Saneamento Basico do Estado de Sao Paulo-SABESP, incorporated on October 6, 1973, is a water and sewage service provider. The Firm provides water and sewage services to a range of residential, commercial, industrial and governmental clients in over 360 municipalities in the state of Sao Paulo, including the city of Sao Paulo. The Company’s divisions include Water and Sewage. The Firm also supplies treated water on a wholesale basis to approximately 10 municipalities located in the Sao Paulo metropolitan region and urban conurbations.

Another recent and important Stratec Biomedical AG (ETR:SBS) news was published by Nature.com which published an article titled: “Anaerobic oxidation of methane associated with sulfate reduction in a natural …” on December 04, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>